Connect with us

Hi, what are you looking for?

Wednesday, Dec 8, 2021
Mugglehead Magazine
Cannabis & psychedelics industry news based in Vancouver, B.C.
  • Loading stock data...

Industry update

Aphria stock hits 2-year high on record Q2 sales

The firm’s valuation is rocketing along with most pot stocks, but uncertainty remains if it can better capitalize on both domestic and international markets

Aphria stock hits 2-year high on record Q2 sales

Canadian producer Aphria Inc.‘s (TSX and Nasdaq: APHA) market valuation catapulted over 20 per cent Thursday — to $15.25 on the Toronto Stock Exchange, its highest since November 2018 — boosted by strong sales and ongoing momentum from Democrat-buoyed optimism for federal cannabis reform in the U.S.

Meanwhile, soon-to-be-acquired peer Tilray, Inc. shot up over 23 per cent to US$18.56 on the Nasdaq. The all-stock deal to create the world’s largest weed company is expected to close soon.

In its second-quarter 2021 earnings report, Aphria said it made $160.5 million in net revenue, a 10-per-cent increase over the previous quarter.

Read more: Aphria shares tank on weak international sales

Read more: Tilray and Aphria unveil merger plan to create world’s biggest weed firm

The firm reported adjusted earnings before interest, taxes, depreciation and amortization of $12.6 million, increasing 26 per cent in the three-month period.

Net losses totalled $120.6 million, which Aphria attributed to increased operating expenses. Rising to $82.7 million from $54.5 million in the previous quarter, the company said the amount was mostly due to transaction costs of $22.6 million associated with the acquisition of U.S. beer maker SweetWater, and increased share-based compensation largely driven by its increase in stock price.

Read more: Analyst lukewarm on Aphria’s US$300M SweetWater acquisition

Aphria says it ended the quarter with a strong balance sheet and liquidity, including $320.0 million of proforma cash to fund planned Canadian and international growth.

But most of the licensed cannabis producer’s growth was driven by its European pharmaceutical business. Net cannabis revenues were reported at $67.9 million, a quarterly increase of just 7 per cent.

In a conference call Thursday morning, analyst Pablo Zuanic of Cantor Fitzgerald asked if the merger with Tilray gave it any more advantage at the local level in Canada.

While Aphria CEO Irwin Simon admitted Tilray is “asset light,” he said merging with the other producer brings in great management as well as a combined market share of over 20 per cent.

“For the period of August to October 2020, the combined company would have a market share approaching 20 per cent, the largest share held by any single licensed producer in Canada and 700 basis points higher than the next closest competitor,” Simon said on the call. “While we’re pleased to be in this position together, we’re striving to be at least 30 per cent market share over time.”

Simon’s estimate puts Canopy’s share of the Canadian market at 13 per cent.

Top image via Aphria

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Nick Laba on Twitter

nick@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can

Canada

As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices

Culture

Punishments for possession include caning and the death penalty. Despite a global trend of reform, The Fine City remains staunch in its anti-drug stance

Analysis

While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe